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Effect of methylprednisolone injection on interleukin-4 and interferon-gamma
expression following hepatitis B vaccination in mice
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Background/aim: The prevalence of hepatitis B infection is high worldwide with liver cirrhosis and hepatocellular carcinoma as important
complications. Immunosuppression, especially from corticosteroids, is often cited as a cause of poor immune response and there is
documented evidence of irrational administration of glucocorticoids to children and adults. Decreased expression of interleukin-4 and
interferon-gamma is an indication of poor humoral and cellular immune responses, respectively. Therefore, we decided to find out if
methylprednisolone injection decreases interleukin-4 and interferon-gamma expression following hepatitis B vaccination in mice.
Materials and methods: Mice were randomly divided into 2 groups. Daily intramuscular injections of methylprednisolone (15 mg/
kg) were given to the test group while water for injection (0.1 mL) was given to the control group for 30 days. On day 6 all mice were
given 2 µg of hepatitis B vaccine and they received a booster dose on day 27. On day 34, blood samples were collected and analyzed for
interleukin-4 and interferon-gamma titers.
Results: There was positive interleukin-4 and interferon-gamma response in all groups but the differences in titers were not statistically
significant.
Conclusion: At the dosages and length of exposure used in this study, methylprednisolone injection did not significantly inhibit
interleukin-4 and interferon-gamma expression following immunization against hepatitis B virus in mice.
Key words: Hepatitis B vaccine, interleukin-4, interferon-gamma, immune response, methylprednisolone

1. Introduction
Hepatitis is a general term meaning inflammation of
the liver and viruses are the most important causes.
The causative organism of viral hepatitis B is a doublestranded DNA virus 42 nm in diameter belonging to the
family Hepadnaviridae. It is transmitted through contact
with blood or other body fluids of an infected person.
Homosexuals, heterosexuals with multiple sex partners,
persons who receive frequent blood transfusions, health
workers who handle blood and blood products, and those
who receive tattoos are important risk groups (1). It is 50
to 100 times more infectious than HIV and can survive
outside the body for at least 7 days (2).
Globally, two billion people have hepatitis B infection
and 600,000 of these die yearly (2). Prevalence of the
disease in Nigeria falls between 11.7% and 44.7% (3).
Failure to mount immune response to hepatitis B
vaccination is a common occurrence. Hepatitis B infection
* Correspondence: ughapieces@yahoo.com
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is a major risk factor for development of liver cirrhosis
and hepatocellular carcinoma. It is found in 1/3 of cases of
liver cirrhosis and 1/2 of cases of hepatocellular carcinoma
(2). Chronic HBV infection accounts for 60%–80% of
the world’s primary liver cancers (4). It is second only to
tobacco among all known human carcinogens (5).
1.1. Justification for the study
Immunization failure that exposes vaccinees to this
infection is often attributed to immunosuppression
associated with malnutrition, diseases like HIV/AIDS,
and glucocorticoid therapy. Interestingly, irrational
prescription and administration of glucocorticoids to
infants and children for such ailments like bronchiolitis,
asthma, skin infections, and febrile convulsions is common
in poor and underdeveloped countries. Cytokines such as
interleukin-4 (IL-4) and interferon-gamma (IFN-γ) are
important mediators of immune response and there are
no studies linking glucocorticoid therapy to low IL-4 and
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IFN-γ expression following hepatitis B vaccination, hence
raising the need for this study. The choice of mice for the
study was informed by the ethical issues involved in using
children. Mice also have genetic similarities to humans (6).
1.2. Objectives of the study
The main objective of this study was to determine the effect
of methylprednisolone injection on cytokine expression
following hepatitis B immunization in mice. Specific
objectives included:
•
To determine the effect of methylprednisolone
injection on serum IL-4 titer following hepatitis B
vaccination in mice.
•
To determine the effect of methylprednisolone
injection on serum IFN-γ titer following hepatitis B
vaccination in mice.
1.3. Hypotheses
Null hypothesis: Methylprednisolone injection does not
decrease serum IL-4 and IFN-γ following hepatitis B
vaccination in mice.
Alternative hypothesis: Methylprednisolone injection
decreases serum IL-4 and IFN-γ following hepatitis B
vaccination in mice. The null hypothesis was tested at a
significance level (P-value) of 0.05.
2. Materials and methods
This study was done at the Pharmacology Laboratory,
Nnamdi Azikiwe University Teaching Hospital, Nnewi and
Safety Molecular Pathology Labs Ltd., Enugu, between July
2009 and June 2013. The procedures were in accordance
with guidelines for the care and use of laboratory animals
(7).
2.1. Sample size determination
A sample size of 40 (20 mice per group) at 95% power to
detect a difference between means of 2.5 at a significant
level (alpha) of 0.05 (two-tailed) was chosen using a special
formula for the calculation of sample size for laboratory
animals experiment (8): N = 1 + 2C[s/d]2 , where C =
a constant (7.8) at 0.05 level of significance, s = 2.75
(standard deviation from a similar previous study) (9),
and d = difference between means desired in present study.
2.2. Animal source
Forty mice (22 males, 18 females), 6–8 weeks old and
weighing 28–36 g, were obtained from the animal house
of the Department of Pharmacology, Nnamdi Azikiwe
University. The animals were certified healthy by a
veterinarian, Dr Chijioke A Ezenyeaku, of this university.
Male mice were randomized into two groups of 11 mice per
group. Female mice were also randomized into two groups
of 9 mice per group. Each group was housed in metal cage
of 60 cm × 45 cm × 30 cm. All were allowed free access
to animal feed (Growers, Top Feeds, Nigeria) and clean
drinking water. Left over feed and water were discarded

and cages were cleaned with chlorhexidine antiseptic
solution every 12 h. Artificial light by fluorescent lamp
(Philips, the Netherlands; 18 W) and a light/dark cycle of
12/12 h were maintained. All mice were acclimatized for
2 weeks.
2.3. Drug source /vaccines/assay kits
Methylprednisolone injection (Methysol, Keun Wha
Pharm. Co, South Korea), diazepam injection (Valium,
Roche, USA), and ketamine injection (Ketalar, Popular
Pharmaceuticals, Bangladesh) were procured from Pax
Pharmacy, Onitsha. Hepatitis B vaccine (Euvax B, LG
Life Sciences, South Korea) was procured from the Cold
Chain Office, Health Department, Idemili North Local
Government, Ogidi, Anambra State. IL-4 Mouse ELISA
Kit (Abcam, UK) and IFN-γ Mouse ELISA Kit (Abcam,
UK) were procured from Safety Molecular Pathology
Laboratories Ltd., Enugu.
2.4. Experimental procedure
Each test mouse received 15 mg/kg methylprednisolone
injection IM on alternate hind legs daily for 30 days
(except on the 6th and 27th days). Each control mouse
received 0.1 mL of water for injection intramuscularly on
alternate hind legs for 30 days (except on the 6th day and
27th days). On the 6th day, all mice were given 2 µg (0.1
mL) of hepatitis B vaccine intramuscularly to the hind leg,
and they received a booster dose on the 27th day. On the
34th day, blood samples were collected from all the mice
for analysis.
The male mice were further randomized based on
the length of exposure to methylprednisolone injections
into MT15: male test mice that received 15 mg/kg
methylprednisolone injection daily for 15 days (n = 6), MT30:
male test mice that received 15 mg/kg methylprednisolone
injection daily for 30 days (n = 5), and MC: male control
mice that did not receive methylprednisolone injection (n
= 11). MT15 and MT30 were differentiated by application
of blue and red permanent marks respectively on the
frontal regions. The female mice (9 test, 9 control) were
similarly randomized into FT15: female test mice that
received 15 mg/kg methylprednisolone injection daily
for 15 days (n = 5), FT30: female test mice that received
15 mg/kg methylprednisolone injection for 30 days (n
= 4), and FC: female control mice that did not receive
methylprednisolone injection (n = 9).
The test and control mice received 2 µg (0.1 mL) of
hepatitis B vaccine on the 6th day and a booster dose on
the 27th day (10). An injections chart was maintained
throughout the duration of the experiment. The animals
were weighed before the commencement and at the end of
the experiment. Deaths of animals were recorded.
2.5. Collection of blood samples
On the 34th day all mice were anesthetized, one at a time,
using intramuscular ketamine and diazepam at 50 mg/
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kg and 5 mg/kg, respectively (11). Blood samples were
collected from the saphenous vein of each mouse using the
Hoff method (12). Withdrawn blood samples were quickly
transferred into plain specimen bottles and allowed to clot
naturally. Thereafter, the serum was separated into another
specimen bottle using a micropipette and stored at 2–8 °C
until use.
2.6 Determination of immune response
Assays for serum IL-4 and IFN-γ were done using ELISA
according to the manufacturer’s instructions (Diagnostic
Automation Inc., USA). The optical densities were
converted into international units using digital software,
Gen 5 (Diagnostic Automation, USA), attached to the
microplate reader (Model No DAR 8000. Diagnostic
Automation Inc., USA).
2.7 Statistical analysis
The mean values (±SEM) for the generated data were
calculated. The D’Augostino and Pearson omnibus
normality test was performed on the data. Testing of
statistical significance between test and control groups
of mice was done for IFN-γ and IL-4 using the Mann–
Whitney test. All statistical tests were done using Graph
Pad Prism 5.0 and the results were taken as statistically
significant at P < 0.05.
3. Results
Three male mice died: 1 MT15 on day 7, 1 MT30 on day 18,
and 1 MC on day 25.
There were positive IL-4 and IFN-γ titers in all groups
of mice (Tables 1 and 2), but the differences in titers
were not statistically significant (Tables 3 and 4). There
were also no significant differences for sex or duration of
methylprednisolone exposure in the groups of mice tested
(Tables 3 and 4).
4. Discussion
Serum IFN-γ and IL-4 were detected in all mice groups
studied. There was no statistically significant difference in
serum IFN-γ and IL-4 between the methylprednisoloneexposed and control groups of mice. There were also no
differences in length of exposure between the groups.
This was in contrast to earlier finding in which cellular
immune responses (mediated by IFN-γ) were suppressed
while humoral immune responses (mediated by IL-4)
were enhanced by glucocorticoids (13). Franchimont et al.
demonstrated that dexamethasone blocked IL-12 (Th1)induced STAT-4 phosphorylation without blocking IL-4
(Th2)-induced STAT6 phosphorylation in lymphocytes
and suggested that this might explain the glucocorticoidinduced shift towards Th2 humoral immune response (14).
In addition, Remelts et al. demonstrated that treatment
with dexamethasone injection suppressed systemic
cytokine response in patients with community-acquired
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pneumonia (15), while Mazzocca et al. demonstrated
the inhibitory effect of methylprednisolone injection on
serum IFN-γ levels in umbilical vein endothelial cells (16).
El-Radhi et al. also demonstrated that oral prednisolone
decreased serum concentration of IL-4 below the
sensitivity level in asthmatic children (17).
The high doses of methylprednisolone used in this
study could explain the inability of this drug to increase
the serum IL-4 or decrease the serum IFN-γ titers
since high doses of glucocorticoids could suppress the
hypothalamic–pituitary–adrenal axis with unpredictable
effects on immune function. This unpredictability is
based on the fact that cytokines, which mediate immune
responses, are pleiotropic (one cytokine can exert many
actions) and redundant (different cytokines can exert the
same action), and often influence the synthesis of other
cytokines.
It is also important to note that the effect of
glucocorticoids on gene expression is not very specific.
Glucocorticoids decrease the expression of target genes
that code for proinflammatory and immunostimulatory
cytokines such as IFN-γ by a process called transrepression.
The opposite effect (transactivation), which increases
the expression of these genes, can also be induced by
glucocorticoids. Most glucocorticoids do not distinguish
between transrepression and transactivation in their
mechanisms of action, making it difficult to predict
what their actions on the immune system could be
(18,19). Therefore, in contrast to the traditional view of
glucocorticoids as immunosuppressant hormones, they
are more accurately conceptualized as immunomodulatory
hormones that can stimulate as well as suppress immune
function, depending on the type of immune response, the
immune compartment, and the cell type involved (20).
This nonspecificity in action could partly explain the
findings in this study.
The low levels of serum IL-4 and IFN-γ in most of
the mice could be explained by the fact that mice are not
natural hosts of hepatitis B virus. This notwithstanding,
mice are good experimental models for hepatitis B viral
studies as their hepatocytes do support hepatitis B viral
replication (21).
Adjuvants are often required in order to increase
immune response to hepatitis B vaccines in mice (22). In
fact, Qin et al. demonstrated an increased secretion of antiHBs, IL-12, and IFN-γ when dinucleotide adjuvants were
injected together with hepatitis B surface antigen in mice
(23). Although the use of adjuvants would have increased
the cytokine titers in these mice, they could have equally
confounded the effect of steroids on the immune response,
the main focus of this study.
There were sex differences in serum IL-4 and IFN-γ
levels as the female test (FT) and female control (FC)
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Table 1. Mean ± SEM serum IL-4 titers (pg/mL) in the test and control groups of mice.
Male test (MT)

Male control (MC)

Female test (FT)

Female control (FC)

3.36

3.65

68.32

2.49

31.47

18.96

2.41

2.43

3.07

3.66

57.63

3.91

2.92

2.45

2.64

3.11

14.60

3.41

2.45

4.66

12.88

3.93

68.32

13.74

3.18

2.49

2.41

89.71

2.90

3.11

56.10

10.69

---

----

2.64

3.88

9.30 ± 4.56

5.21 ± 1.94

29.21 ± 10.22

14.96 ± 8.97

The test groups of mice (MT, FT) received daily intramuscular injections of 15 mg/kg
methylprednisolone injections for 30 days. The control groups of mice (MC, FC) received
daily intramuscular injections of 0.1 mL of sterile deionized water for 30 days. All mice
groups received 2 µg (0.1 mL) of HBsAg on the 6th and 27th days.
Table 2. Mean ± SEM serum IFN-γ titers (pg/mL) in the test and control groups of mice.
Male test (MT)

Male control (MC)

Female test (FT)

Female control (FC)

3.55

6.54

34.44

2.98

32.11

23.64

12.18

2.8

8.99

6.42

27.83

4.69

2.33

2.55

3.59

3.37

5.64

5.49

6.13

5.52

2.54

5.73

25.83

16.48

3.11

4.97

4.57

68.70

7.22

2.18

4.99

10.69

----

----

6.25

4.09

8.18 ± 3.47

7.19 ± 2.42

13.98 ± 3.94

13.27 ± 6.70

The test groups of mice (MT, FT) received daily intramuscular injections of 15 mg/kg
methylprednisolone injections for 30 days. The control groups of mice (MC, FC) received
daily intramuscular injections of 0.1 mL of sterile deionized water for 30 days. All mice
groups received 2 µg (0.1 mL) of HBsAg on the 6th and 27th days.

groups had higher average serum IL-4 and IFN-γ levels,
but these differences were not statistically significant when
subjected to statistical analysis.
Limitations encountered in this study include species
differences between man and mice and even genetic
differences between the mice groups; these could account

for some of the conflicting findings. The use of monoclonal
cell lines in place of animals could have eliminated these
species and genetic differences. However, such a study is
beyond the scope of this work in terms of personnel and
laboratory facilities. The sample size of 40 mice is also a
minus in terms of significance of the study to the general
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Table 3. Result of statistical analyses of serum IL-4 titers (pg/mL) in various test
and control groups of mice using the Mann–Whitney test.
Data analyzed

Sum of ranks
in row A

Sum of ranks
in row B

P-value

MT vs. MC

70

66

0.8785

MT15 vs. MT30

18

18

1.000

FT vs. FC

87

84

0.9314

FT15 vs. FT30

27.5

27.50

0.9155

MT vs. FT

84

87

0.5041

The test groups (MT, FT) of mice received daily intramuscular injections of 15
mg/kg methylprednisolone injections for 30 days. The control groups of mice
(MC, FC) received daily intramuscular injections of 0.1 mL of sterile deionized
water for 30 days. All mice groups received 2 µg (0.1 mL) of HBsAg on the
6th and 27th days. MT15, MT30: Male test mice exposed to methylprednisolone
injection for 15 and 30 days, respectively. FT15, FT30: Female test mice exposed to
methylprednisolone injection for 15 and 30 days, respectively.
Table 4. Result of statistical analyses of serum IFN-γ titers (pg/mL) in various
test and control groups of mice using the Mann–Whitney test.
Data analyzed

Sum of ranks
in row A

Sum of ranks
in row B

P-value

MT vs. MC

68

68

1.000

MT15 vs. MT30

20

16

0.6857

FT vs. FC

100

71

0.2224

FT15 vs. FT30

28

17

0.5556

MT vs. FT

84

87

0.5041

The test groups (MT, FT) of mice received daily intramuscular injections of 15
mg/kg methylprednisolone injections for 30 days. The control groups of mice
(MC, FC) received daily intramuscular injections of 0.1 mL of sterile deionized
water for 30 days. All mice groups received 2 µg (0.1 mL) of HBsAg on the
6th and 27th days. MT15, MT30: Male test mice exposed to methylprednisolone
injection for 15 and 30 days, respectively. FT15, FT30: Female test mice exposed to
methylprednisolone injection for 15 and 30 days, respectively.

population. Modification of this study using cell lines in
place of animals can allow a higher sample size to increase
the sensitivity of the study. Further research on this topic
should take the above mentioned limitations into account.
In conclusion, the results show that there were
positive IL-4 and IFN-γ responses in all mice groups,
but the differences in titers between the groups were not
statistically significant. Therefore, it could be concluded
that at the dosages and length of exposure used in this
study, methylprednisolone injection did not significantly
inhibit IL-4 and IFN-γ expression following hepatitis
B vaccination in mice. The possible extrapolation from
this could be that corticosteroids, when used in the usual
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clinical doses and duration of therapy, are not likely
to inhibit immune response to hepatitis B and other
vaccinations. This is more likely to be so since doses and
duration of therapy higher than those that are usually
applied in clinical practice were used in this study with
no statistically significant reduction in antibody and
cytokines responses.
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